POPULATION PHARMACOKINETIC ANALYSIS OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA OR ADVANCED SOLID TUMORS

Gunawan R.; Badros A.; Papadopoulos K.; Siegel D.; Jagannath S.; Vij R.; Niesvizky R.; Ou Y.; Wang Z.; Rajangam K.; Garnett C.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >POPULATION PHARMACOKINETIC ANALYSIS OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA OR ADVANCED SOLID TUMORS

【24h】

POPULATION PHARMACOKINETIC ANALYSIS OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA OR ADVANCED SOLID TUMORS

机译：复发或复发且难治性多发性骨髓瘤或晚期实体瘤患者卡非昔布的种群药动学分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2014年第1期|共1页
作者
Gunawan R.; Badros A.; Papadopoulos K.; Siegel D.; Jagannath S.; Vij R.; Niesvizky R.; Ou Y.; Wang Z.; Rajangam K.; Garnett C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. POPULATION PHARMACOKINETIC ANALYSIS OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA OR ADVANCED SOLID TUMORS [J] . Gunawan R., Badros A., Papadopoulos K., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：复发或复发且难治性多发性骨髓瘤或晚期实体瘤患者卡非昔布的种群药动学分析
2. Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials [J] . Mateos Maria-Victoria, Goldschmidt Hartmut, San-Miguel Jesus F., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在先前治疗之后复发或难治多骨髓瘤患者的复发或难治性多发性骨髓瘤患者：分析来自随机阶段3的亚群的整体存活率，渴望和努力试验
3. POPULATION PHARMACOKINETICS OF RELATLIMAB, A FULLY HUMAN LAG-3-SPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND RELAPSED OR REFRACTORY B-MALIGNANCIES. [J] . Zhang J., Bathena S. P., Chapel S., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：Relatlimab的人口药代动力学，一种完全人滞3个特异性抗体，高级实体瘤患者和复发或难治性B-恶性肿瘤。
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study [O] . Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, 2021

机译：Carfilzomib在先进的复发/难治性多发性骨髓瘤中提高骨代谢：Carmma研究的结果
7. A phase I/ II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort [O] . Jesus G. Berdeja, Tara K. Gregory, Edward A. Faber, 2021

机译：一期I / II研究Panobinostat和Carfilzomib在复发或复发/难治多骨髓瘤患者中的组合：第二剂量 - 膨胀队列的最终分析

POPULATION PHARMACOKINETIC ANALYSIS OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA OR ADVANCED SOLID TUMORS

著录项

相似文献

相关主题

期刊订阅